Beam Therapeutics Inc (BEAM)

09:43 AM

Beam Therapeutics Inc. Stock Analysis and ForecastFree Wealth Management Insights - Autocar Professional

09:43 AM

Jul 22, 2025

What drives Beam Therapeutics Inc. stock priceDynamic investment opportunities - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What analysts say about Beam Therapeutics Inc. stockFree High-Return Strategy Alerts - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is Beam Therapeutics Inc. a good long term investmentRobust financial gains - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025

Jul 21, 2025

Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN

Jul 21, 2025

Jul 16, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 16, 2025

Jul 14, 2025

(BEAM) Trading Report - news.stocktradersdaily.com

Jul 14, 2025

Jul 13, 2025

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN

Jul 13, 2025

Jul 08, 2025

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT - MSN

Jul 08, 2025

Jul 07, 2025

Cathie Wood’s ARK ETF bolsters Beam stock, sheds Roblox - Investing.com

Jul 07, 2025

Jul 06, 2025

Beam Therapeutics: A Base Editing Breakthrough With Catalysts to Ignite Value - AInvest

Jul 06, 2025

Jul 04, 2025

Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN

Jul 04, 2025

Jul 04, 2025

Beam Therapeutics Acquires Early-Stage Life Sciences Firm - The Globe and Mail

Jul 04, 2025

Jul 01, 2025

H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target - Investing.com

Jul 01, 2025

Jun 30, 2025

Beam Therapeutics: A Contrarian Opportunity in Gene Editing Amid Russell Reconstitution - AInvest

Jun 30, 2025

Jun 30, 2025

Top 10 CRISPR Stocks to Buy Now - Insider Monkey

Jun 30, 2025

Jun 30, 2025

Beam Therapeutics Inc.(NasdaqGS: BEAM) dropped from Russell 3000 Value Index - MarketScreener

Jun 30, 2025

Jun 27, 2025

3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail

Jun 27, 2025

Jun 24, 2025

BEAM-101 shows sustained benefits as treatment for sickle cell - Sickle Cell Disease News

Jun 24, 2025

Jun 20, 2025

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha

Jun 20, 2025

Jun 19, 2025

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance

Jun 19, 2025

Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025

Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo Finance

Jun 18, 2025

Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025

Jun 17, 2025

BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com

Jun 17, 2025

Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 16, 2025

Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com

Jun 16, 2025

Jun 14, 2025

Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria

Jun 14, 2025

Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clini - GuruFocus

Jun 13, 2025

Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire

Jun 13, 2025

Jun 13, 2025

Beam Therapeutics (BEAM) Reports Strong Results for Sickle Cell Therapy - GuruFocus

Jun 13, 2025

Jun 13, 2025

Beam reports positive results from sickle cell disease treatment - Seeking Alpha

Jun 13, 2025